Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeyondSpring Starts Rolling Application of China NDA for Neutropenia Treatment

publication date: Mar 31, 2020

BeyondSpring, a New York City biopharma that develops drugs for the US and China, has started a rolling submission of a China NDA for Plinabulin to treat chemotherapy-induced neutropenia. The Phase III trials tested Plinabulin compared to Neulasta, a granulocyte-colony stimulating factor, or together with Neulasta and compared to Neulasta alone. GSCFs have been the standard of care for CIN for 30 years. BeyondSpring expects to submit an NDA in the US for the same indication in the second half of 2020. More details....

Stock Symbol: (NSDQ: BYSI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.